Todd Kinsella
Corporate Officer/Principal presso Vividion Therapeutics, Inc.
Posizioni attive di Todd Kinsella
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
Vividion Therapeutics, Inc.
 Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Corporate Officer/Principal | 01/12/2017 | - |
Storia della carriera di Todd Kinsella
Precedenti posizioni note di Todd Kinsella
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| RIGEL PHARMACEUTICALS, INC. | Direttore Tecnico/Scientifico/R&S | - | - |
Formazione di Todd Kinsella
| University of Arizona | Undergraduate Degree |
| Stanford University | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
Posizioni
| Corporate Officer/Principal | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Undergraduate Degree | 1 |
Settori
| Consumer Services | 3 |
| Commercial Services | 2 |
| Health Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| RIGEL PHARMACEUTICALS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Vividion Therapeutics, Inc.
Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Commercial Services |
- Borsa valori
- Insiders
- Todd Kinsella
- Esperienza
